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Abstract
Amgen is a biotechnology company with manufacturing plants throughout the world. New man-
ufacturing technologies are constantly being developed and implemented in order to address cost,
quality, regulation, and competitive forces. However, deciding on the technologies to implement
is difficult because there is much uncertainty and the regulatory constraints of old products need to
be balanced with the need of manufacturing flexibility for new products.
Interviews were conducted with executives at Amgen and other biotechnology companies to
understand their current decision-making processes and no gold-standard decision-making process
emerged. The current process at Amgen is a business case along with net present value (NPV).
However, the process has been found to be somewhat biased and decisions are often made on
gut-instinct and excitement. In addition, the business case often fails to capture some of the more
subjective, intangible elements of new technologies. Therefore, a technology decision-making
framework based on the Analytic Hierarchy Process (AHP) is introduced.
The AHP is an objective, group decision-making approach. For usability and sustainability,
commercial software from Expert Choice was used in case studies to validate AHP as a decision-
making approach within Amgen. One case study looked at options to upgrade a clinical manufac-
turing facility. An AHP model was analyzed simultaneously with a typical business case and NPV
analysis. The AHP model allowed management to understand the more subjective areas where the
options differed and therefore was a suitable approach that added value. Another case study was
performed looking at choosing a standardized drug substance container where five previous anal-
yses had been performed, but no decision made. The AHP model allowed the different criteria to
be combined in one model with cross-functional input so that management could make a holistic
decision. The AHP approach had many benefits and using commercial software made the process
easier for users and allowed for a more sustainaible process within Amgen.
Thesis Supervisor: Charles Cooney
Title: Robert T. Haslam Professor of Chemical Engineering, Department of Chemical Engineering
Thesis Supervisor: Roy Welsch
Title: Professor of Statistics and Management Science, Sloan School of Management
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Chapter 1. Introduction
The pharmaceutical industry generally produces two kinds of pharmaceuticals: small molecules
and macromolecules, which are also known as biologics. Small molecule pharmaceuticals, such
as penicillin, are typically produced through defined chemical processes or purified from microbes
and are typically delivered orally in pill or tablet form. Macromolecule pharmaceuticals are more
complicated to produce because their production involves the generation of the active pharmaceu-
tical ingredient (API) from bacteria, fungal, insect, or mammalian cells, and must be purified from
the rest of the cellular material through several chromatography steps. The API is typically a liq-
uid, known as bulk drug substance, which is then formulated into a drug product in order to be
delivered non-orally. There are many technologies used throughout the production of biologics.
This thesis will focus on the issues around investing in biologic manufacturing technologies and
how using the Analytic Hierarchy Process can improve the decision-making process.
Amgen, Inc. is a biotechnology company headquartered in Thousand Oaks, CA that discovers,
develops, manufactures, and markets drugs for the treatment of various diseases. These drugs are
mostly biologics. It has one clinical manufacturing facility located in Thousand Oaks, CA and sev-
eral commercial manufacturing sites located in the United States, Europe, and South America. As
with other healthcare companies, Amgen has to constantly make decisions on which technologies
it will invest in, which place it should introduce new technologies, which products it will advance
out of research, and which new technologies may be required for each new product.
This thesis describes a tool to make more objective assessments and decisions around new
technology introduction in order to help management make the right decisions in a timely manner.
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1.1 Problem Statement
The biologics manufacturing process is complex. Recently, several factors have caused the biotech-
nology industry to undertake numerous changes to how it produces these drugs. These reasons
include regulatory requirement changes, improvements in manufacturing technology, new types of
active pharmaceutical ingredients, patient safety, and the need to decrease costs in order to improve
margins. In addition, to maintain good standing with regulatory agencies, pharmaceutical compa-
nies must ensure they are maintaining current good manufacturing processes (cGMP). Since what
is defined as "current" changes over time, companies must continually evaluate their processes and
add technologies and equipment where needed. This often involves retrofitting existing technology
and/or facilities and can even involve the need to build a new manufacturing plant.
New technology usually follows a pre-defined path through an organization from research to
commercial implementation (or from small-scale to large-scale) as shown in Figure 1. A new
technology typically begins in research where it is characterized and tested. It then progresses
through process development and a pilot plant, which is a very scaled-down manufacturing plant.
Technology then progresses to the clinical manufacturing facility, which produces bulk drug sub-
stance and drug product for clinical trials around the world and also supports the lifecycle needs of
commercialized products. Finally, once a technology is well understood, it can be introduced into
commercial manufacturing facilities. It usually follows this path because of increasing regulatory
burdens as a technology progresses into clinical and commercial operations and the cost is greater
the larger the scale of the technology. However, this pathway is not always taken and the realizable
value of new technology coming out of research is not always clear due to high complexity and
long implementation schedules.
Several questions arise from the need to implement new technologies:
* What technologies will be needed for future products?
" Which of several technologies to choose?
" Where to introduce the new technologies?
" When to introduce the new technologies?
" How does implementation affect current processes?
" Balancing the cost of new technologies with the benefits?
14
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Figure 1: Typical progression of technology through a pharmaceutical company. Technology usually pro-
gresses through five stages of the research and operations departments. Research and develop-
ment, process development, and the pilot plant are the first three steps in research while clinical
manufacturing and commercial manufacturing are the two steps in operations.
Amgen realizes that in the past they have not always answered the above questions using a
robust set of factors or impacts. This occurs at many companies and can be the result of an in-
adequate decision-making process. Decisions can be biased when the decision-making process
involves people from different groups throughout an organization. In addition, depending on who
sponsors an assessment, the analysts may propose the option that they feel their boss wants. Fur-
thermore, sometimes the decision-maker has a "feeling" about what they want the outcome of
the analysis to be and therefore they may overly influence the process so that what they want is
selected. Finally, sometimes the person who is excited about a certain technology or has a "gut
instinct" about the right answer pushes it through the decision-making process without a truly ob-
jective assessment. Thus, Amgen is looking for an unbiased decision-making process that can be
both comprehensive and sustainable.
1.2 Hypothesis
This thesis proposes a strategic framework that can evaluate many aspects of new manufacturing
technology in an objective manner. The decision-making process to answer the above questions
needs to be robust while being simple, quick, easy-to-understand, and easy-to-use so that the right
decision is made in a timely manner. If management can analyze both subjective and objective
criteria that can be tangible or intangible, then they can make better decisions with greater under-
standing. The project focused on evaluating technologies for implementation in Amgen's clinical
bulk drug substance manufacturing and clinical formulate / fill / finish drug product manufacturing.
15
1.3 Organization of Thesis
This thesis is organized into 6 chapters as described below:
Chapter 1 Gives an overview of the problem and briefly discusses the hypothesis that was tested
at Amgen, Inc.
Chapter 2 Discusses the biotechnology industry and Amgen
Chapter 3 Explores the current processes used for decision-making at Amgen and other compa-
nies and discusses issues with innovating, specifically with regards to decision-making and
implementation
Chapter 4 Explains the framework used to make objective decisions and the commercial software
used during the project that implements the framework
Chapter 5 Discusses the results of three case studies performed using the new framework
Chapter 6 Concludes the thesis and makes recommendations for future applications
16
Chapter 2. Background and Context
The biopharmaceutical industry is generally composed of two industries - the pharmaceutical
industry and biotechnology industry. The industry is highly competitive as can be seen in Table 1,
which lists the market share and sales of the top 15 global companies in the biopharmaceutical
industry.
Table 1: Global Sales of Top Biopharmaceutical Corporations. Sales are in US$ with quarterly exchange
rates and cover direct and indirect pharmaceutical channel wholesalers and manufactures. The
figures include prescription and certain over the counter data and represent manufacturer prices.
Adapted from IMS Health Midas, December 2010 [1]
2010 Market 2010 Sales 2009 Sales
Top Corporations Share (%) (US$ MN) (US$ MN)
Global Market 100 791,449 752,022
Pfizer 7.0 55,602 57,024
Novartis 5.9 46,806 38,460
Merck & Co 4.9 38,468 38,963
Sanofi-Aventis 4.5 35,875 35,524
Astrazeneca 4.5 35,535 34,434
GlaxoSmithKline 4.3 33,664 34,973
Roche 4.1 32,693 32,763
Johnson & Johnson 3.4 26,773 26,783
Abbott 3.0 23,833 19,840
Lilly 2.8 22,113 20,310
Teva 2.7 21,064 15,947
Bayer 2.0 15,656 15,711
Amgen 2.0 15,531 15,038
Bristol-Myers Squibb 1.9 14,977 14,110
Boehringer Ingelheim 1.9 14,591 15,275
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The pharmaceutical industry has existed for centuries and includes companies that generally
manufacture and market small molecule pharmaceuticals. Small molecule pharmaceuticals are
produced through defined chemical processes. The small molecule API is then typically com-
bined with other inactive chemicals in pill or tablet form to be delivered orally to a patient; how-
ever, sometimes they are delivered intravenously as is done for some chemotherapy agents. Small
molecule pharmaceuticals are typically marketed as either brand name or generic drugs. Brand
name drugs are those marketed and manufactured by the drug's original patent holder. After the
patent for a small molecule pharmaceutical expires, other companies typically manufacture and
sell the drug as a generic at a reduced price since they did not have to bear the research and de-
velopment costs of the drug. Therefore, the majority of revenue received for a small molecule
pharmaceutical occurs between when the product is first introduced to the market and the patent
expires. Generic drugs are attractive for companies to produce because no regulatory clinical trials
are required since the manufacturing process is chemically defined.
The biotechnology industry is much younger than the pharmaceutical industry as it has devel-
oped over the last century since the discovery of the central dogma of molecular biology. Biotech-
nology companies generally manufacture and market macromolecule pharmaceuticals, also known
as biologics, which are produced from bacterial, fungal, insect, or mammalian cells. The API from
the cells is purified from the rest of the cellular material through several chromatography steps as
described in Section 2.1.1. During these steps, several enzymatic modifications may be performed
on the molecule such as adding or removing functional groups from its carbohydrate structure. The
result of the purification process is a liquid product, known as bulk drug substance, which must
then be formulated into a drug product that is typically delivered by injection. Since the biologic
manufacturing process is not chemically defined, other companies cannot identically replicate the
product after a molecule's patent expires; therefore, there are no generic biologics, but companies
are interested in creating near-identical molecules called biosimilars. However, because of the high
cost of biologics for patients, there has been growing support for a regulatory pathway to approve
biosimilars.
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There are significant differences between the two industries other than the molecular size of
the product. Over the last decade, the biopharmaceutical industry has seen increased global yearly
revenue as shown in Figure 2; however, over the same time period the growth rate year-over-
year has declined [2]. This is largely due to expiring small molecule patents, pricing pressures,
increased generic competition, and fewer new drug discoveries and regulatory approvals in the
pharmaceutical industry [3, 4]. Thus, pharmaceutical industry revenue growth was only 1% in
2010 whereas the biotechnology industry revenue growth was 10% in 2010 [5, 6]. Therefore, the
older, larger pharmaceutical industry has increasingly sought to merge and acquire biotechnology
companies as shown in Figure 3 or develop their own biotechnology ventures. Thus, an increasing
number of companies are involved in both the pharmaceutical and biotechnology markets. The
factors affecting the overall industry and its increasing focus on biotechnology are described in
more detail in Section 2.2.
Biopharmaceutical Industry: Revenue Forecast (World), 2001-2011
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Figure 2: Biopharmaceutical Industry Revenue from 2001-2011. The revenue from selling biopharmaceu-
ticals has been increasing from about $400B to about $890B while the yearly revenue growth rate
has decreased from about 12% to about 5%. [2]
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Announced Mergers & Acquisitions: Biotechnology & Pharmaceuticals, 1988 - 2010
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Figure 3: Announced Mergers & Acquisitions: Biotechnology & Pharmaceuticals, 1988-2010. The num-
ber of mergers and acquisitions in the biotechnology and pharmaceutical industry has steadily
increased [7]
2.1 Biotechnology Industry Overview
The biotechnology industry is relatively young and is primarily composed of companies working
on human health technologies, such as biologic drugs, as shown in Figure 4. However, the industry
also includes companies using biotechnology in other applications like energy and agriculture.
Nevertheless, this thesis focuses purely on the medical biotechnology industry.
As shown in Figure 4, the two largest biotech companies are Roche and Amgen, Inc. Over the
last decade, revenue growth has been positive (except for the recession period of 2008-2009), and
it is forecased to increase over the next decade. Employment in the industry has been relatively
constant while the dollars spent on research and development has increased slightly year-over-year
except for the 2008-2009 period [5].
The industry is complex and undergoing many changes. Key market drivers are an increased
use of specialty pharmaceutical products, the expansion of emerging country markets, blockbuster
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Figure 4: Biotechnology Industry Overview [5]
revenue performance, and population factors such as an increasing proportion of people over age
65 and a better understanding of patient subsets through diagnostic tests. On the other hand, mar-
kets are restrained by maturation of developed countries to slow/low growth at the macro level,
biosimilar/biogeneric emergence on the global stage, and increased scrutiny and impact from pay-
ers and health technology economic assessments [3].
As mentioned above, there have been numerous mergers and acquisitions within the biotech-
nology industry due to the promising nature of future medical treatments from biotechnology. This
includes advances to treating current diseases and also the prospect for discovering medicines with
new technologies such as stem cells, gene therapy, and personalized medicine. Biotechnology
companies are looking to use these new technologies to treat diseases such as cancer by finding
specific biomarkers to more specifically target treatment. Other major disease target areas are
HIV/AIDS, Hepatitis C, drug-resistant infections, diabetes, Alzheimer's disease, and autoimmune
diseases such as rheumatoid arthritis and multiple sclerosis [4].
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Most companies currently focus their manufacturing and selling activities to the developed
world due to intellectual property issues and the ability of patients to pay for the cost of the drugs
sold. However, due to the current climate in the United States and Europe about the increasing
cost of healthcare, there has been increasing pressure to reduce the cost of medicines and explore
new markets for growth. Therefore, companies are beginning to look to Asia, Latin America, and
Eastern Europe for both manufacturing and marketing drugs, specifically the emerging markets of
Brazil, Russia, India, and China [3, 4].
2.1.1 Biologics Manufacturing Process
The process of making a biologic drug is complex and varies depending on the particular molecule
being produced. However, there are standard processes that must be performed for every biologic
as described in Figure 5. There are four main steps to the production of a biologic - cell cul-
ture, purification, formulation, and filling. The pharmaceutical molecule is made during the cell
culture process by growing bacterial, fungal, or mammalian cells in a bioreactor. Depending on
the process, the pharmaceutical may be contained within the cells or it may be secreted into the
media in which the cells grew. There are two typical production methods for growing the cells in a
bioreactor - batch and perfusion. The batch method involves growing cells for a certain period of
time in the bioreactor and then taking all the cells out of the reactor for the next step of the process,
purification. The perfusion method involves growing the cells for a longer period of time in the
bioreactor while continuously extracting cells and adding growth media at steady state. Once the
pharmaceutical ingredient has been produced by the cells in either a perfusion or batch bioreactor,
several purification steps are performed in a batch manner.
The purification process occurs after the cells and/or supernatant liquid are taken from the
bioreactor. The cells and/or liquid are then put through different types of chromatography columns
in order to separate the actual pharmaceutical from the rest of the cellular material and liquid.
These chromatography columns usually work on principles of size exclusion, anion exchange,
affinity, or pH balance. Numerous support operations are required to keep the cell culture and
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Figure 5: Making a Biotech Drug. The basic steps for the production of Genzyme's Cerezyme biologic are
shown: cell culture, media preparation, protein purification, buffer preparation, and fill/finish.
Other support functions include automation engineering, metrology, validation, quality con-
trol, quality assurance, maintenance, facilities engineering, manufacturing technical support.
Adapted from [8].
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purification operations going including buffer preparation, media preparation, cleaning operations,
facilities engineering, maintenance, metrology, validation, quality assurance, quality control, and
automation engineering. Buffer and media preparation involve mixing large amounts of chemicals
with water in tanks and then storing them for use during the production process. The cleaning
operations involve cleaning using caustic chemicals or steaming and in commercial manufacturing
is typically done through running clean-in-place (CIP) and steam-in-place (SIP) skids. Metrology
involves calibrating the various equipment used in the plant while validation ensures processes are
standard and repeatable. Facilities engineering and maintenance repair any equipment issues and
keep the building operating efficiently. Quality assurance and quality control ensure all standard
operating procedures are performed and that the process is performing to specifications. Automa-
tion engineering programs and controls the various automated tasks that run in the plant.
Once the molecule is purified it exists as a liquid known as bulk drug substance. The bulk drug
substance must then be formulated to the correct dosage through dilution or concentration of the
solution. Finally, the liquid is filled into vials or another type of delivery mechanism such as a
syringe for doctors to deliver to patients. Sometimes the liquid product is freeze-dried in a process
known as lyophilization in order to increase the shelf-life of the product. Large molecules cannot
be delivered orally and instead must be delivered into the bloodstream or muscle. Therefore, the
typical administration of a biologic is through a needle injection or intravenous bag in a doctor's
office or hospital rather than a pill. More recently, next-generation delivery mechanisms have been
researched in order to make the delivery of a biologic to patients easier.
2.2 Factors Influencing Industry Change
There are numerous forces causing the industry to change how it manufactures its biologics. The
forces can be summarized into regulatory, economic, safety, efficiency, and environmental factors.
These forces have spurred the research and development of new manufacturing technologies that
companies need to decide between and how to implement.
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2.2.1 Regulatory Factors
The biopharmaceutical industry is heavily regulated to ensure patient safety. Each country has
their own regulatory process that oversees pharmaceutical and biotechnology drug approvals. Reg-
ulatory agencies are tasked with approving new drugs and ensuring that companies have current
good manufacturing practices (cGMPs). For this reason, companies must continually evaluate and
invest in manufacturing technology in order to satisfy regulations. The most prominent drug regu-
latory agencies are the Food and Drug Administration (FDA) of the United States of America, the
London-based European Medicines Agency (EMEA) of the European Union, and the Ministry of
Health, Labor, and Welfare of Japan [9].
The drug approval process requires at least three phases of human clinical testing. In phase
I, a small number of healthy individuals are given the drug to test safety and dosing. In phase II,
a larger number of people who have the disease are tested to identify efficacy, safety issues, and
optimal dosing. Finally, in phase III, an even larger number of patients with the disease are used to
test the drug in placebo-controlled trials to statistically show that the drug is efficacious and safe
[9]. The whole process of moving a drug from phase I to the end of phase III could take 10-15
years and sometimes post-approval studies are required as well.
Most clinical trials are placebo-controlled in order to ensure any measured effect of the drug
is actually due to the drug and not some other factor. Placebo-controlled trials involve giving one
set of patients a placebo or inert substance while the other set of patients receives the drug being
tested. The patients who receive the drug and those who receive the placebo are often randomly
assigned. Frequently, the trials are performed double-blind, which means neither the patient nor
the doctor knows who is receiving the drug and who is receiving the placebo, in order to remove
any possibility for bias. The manufacturing process for a drug typically must be finalized once a
drug reaches phase III clinical trials because there is no other regulatory approval step between
phase III trials and marketing a drug to patients. If a part of the process must be changed after the
phase III clinical trials, companies must show that the change does not materially affect the drug
produced, which can be both costly and time-consuming.
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The FDA and other regulatory agencies frequently inspect manufacturing plants in order to
ensure that drugs are manufactured in the safest manner for patients. Over the last few years,
these agencies have given warning letters to pharmaceutical and biotech manufacturers after they
inspect and find deficiencies in their operations. Companies that receive a warning letter are given
a certain amount of time to correct the deficiencies. If the deficiencies remain, then the FDA
can give a company a consent decree, which means the government takes over the operations
of the manufacturing facility for a specified time. The purpose is to ensure patient safety while
jointly implementing a plan to remediate the manufacturing plant and return it to company control.
A prominent case occurred in 2008 when the FDA gave Genzyme Corporation a warning letter
followed by a consent decree for various reasons after the site was contaminated with a virus and
had to be shut down for several months [10, 11]. One significant concern was their maintenance of
equipment, but it also related to Genzyme not keeping up with the newest manufacturing processes.
At the end of 2009, Genzyme had to send a letter to doctors warning them of foreign particles in
their filled vials [12]. The foreign particles could have been prevented or reduced with a new
technology called isolators, which is the subject of the case study in Section 5.2. This is just one
example for why companies need to constantly evaluate their manufacturing technology in order to
ensure they are following current good manufacturing practices, and not just good manufacturing
practices, so that they remain in good standing with regulatory agencies.
2.2.2 Economic Factors
There are two economic motivating factors for the need to implement new manufacturing technolo-
gies - rising costs and decreasing revenue. While pharmaceuticals and biologics enjoy healthy
margins while the drug is under patent protection, these margins are being threatened.
The average cost to research and develop a new drug and bring it through clinical trials to
market has risen exponentially over time as shown with inflation-adjusted dollars in Figure 6a
[13]. In addition, Adams and Bratner have compiled several studies looking at the cost of new drug
development showing that the cost has increased over time as shown in Figure 6b [14]. The cost of
26
a drug is high because relatively few drugs make it from research through clinical trials and thus the
cost of one approved drug also includes the cost to develop the ones that failed. Companies need
to invest in new technologies in order to achieve better research and manufacturing efficiencies to
decrease the cost of bringing a drug to market.
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The amount of revenue that companies can achieve for every drug is being pressured due to
patents expiring, increased competition, and fewer approvals. Companies have relied on block-
buster drugs that provide billions in revenue per year while under patent protection to fund future
research. However, the patents for many of these blockbuster drugs are nearing expiration as shown
in Figure 7. Once a patent expires and generic competition begins, the typical margin of 80-90%
drops to about 5%. Since there is no regulatory framework for biosimilars, this does not occur
as much in the biotechnology industry. However, because biologics can cost tens or hundreds of
thousands of dollars per year per patient and the cost of healthcare is rising, the FDA and other reg-
ulatory agencies are looking at mechanisms to implement biosimilars as described in Section 2.2.3
in order to introduce competition and reduce the amount patients have to pay and which in turn
will reduce revenues.
In addition, while Figure 6a shows that up to the year 2000 the number of molecules approved
by the FDA has increased slightly over time, this trend has decreased in the last decade as shown
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in Figure 8, because the FDA has started to require more from companies looking for a new drug
approval. Rather than just allow a follow-on molecule that treats a disease in a similar way, the FDA
is beginning to require new drugs to be either more efficacious or safer in order to be approved.
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Figure 7: Patent Expiries and effect on Worldwide Pharmaceutical Sales. A large number of patents are
expiring in the first half of 2010s that puts 4-10 percent of drug sales at risk.
2.2.3 Other Factors
There are several other factors influencing the need for new manufacturing technology such as
environmental concerns, capacity, efficiency, personalized medicine, and biosimilars. Current pro-
duction processes as described in Section 2.1.1 utilize equipment that must be cleaned and steril-
ized using thousands of gallons of water per day. The large amount of operations performed per
day requires several hours to clean and sterilize equipment that results in production downtime.
The cleaning and other peripheral equipment also takes up much space. Thus, the industry is look-
ing at moving towards single-use equipment instead of stainless steel equipment that is widely
used today. The single-use equipment could be recycled and could have numerous benefits such as
less water usage, less downtime between operations, less storage space, and greater flexibility to
make changes.
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Figure 8: FDA Drug Approvals from 1994-2010. The black line represents the number of new drug appli-
cations (NDAs) each year and the gray line represents the number of new drugs approved each
year The number of new drugs approved each year has trended downward. [9]
The human genome project, which was completed around 2001, mapped the nucleotide se-
quence of human DNA and it has spurred innovation in technology that allows for quick, cost-
effective genetic testing of human diseases. This is beneficial because more and more diseases,
such as cancers, are found to be caused by DNA mutations. Thus, cancer is thought of not as one
disease, but as many different diseases caused by many different mutations. Thus, as the cost and
time to sequence DNA decreases, doctors will be able to personalize medicine and companies can
create drugs that are tailored for specific genetic causes. These personalized medicines would prob-
ably have to be manufactured cost-effectively since they would be produced in smaller quantities.
Therefore, new technologies such as smaller, single-use equipment will need to be implemented in
order to more economically produce smaller quantities of a drug.
The growing support for regulatory agencies to create a pathway for biosimilars, which will
result in competition for biologics and lower margins, will require more efficient manufacturing
methods. Thus, manufacturers are beginning to look into methods to continuously manufacture bi-
ologics by making the drug purification process as continuous as the perfusion bioreactor process.
Novartis and the Massachusetts Institute of Technology have created a 10-year research collabora-
tion called the Novartis-MIT Center for Continuous Manufacturing in order to study how to enable
continuous manufacturing for biologics. They state that the benefits of continuous manufacturing
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are [15]:
" Accelerating the introduction of new drugs through efficient production processes
" Requiring the use of smaller production facilities with lower building and capital costs
e Minimizing waste, energy consumption, and raw material use
" Monitoring drug quality on a continuous basis rather than through post-production, batch-
based testing
" Enhancing process reliability and flexibility to respond to market needs
Much research beyond this initiative is taking place across the industry in order to achieve
continuous manufacturing and other technological advances to pharmaceutical manufacturing to
achieve the above results.
2.3 Amgen
Amgen, Inc. is a biotechnology company headquartered in Thousand Oaks, CA that discovers, de-
velops, manufactures, and markets drugs (mostly biologics) for the treatment of various diseases.
Founded in 1980, it has grown to approximately 17,000 employees with 2010 revenues of $15.1 bil-
lion, 2010 product sales of $14.7 billion, and 2010 R&D expense of $2.9 billion. Amgen's main re-
search facilities are located throughout the United States, Canada, United Kingdom, and Germany.
Through research and acquisitions Amgen's principal products are the following: Aranesp@
(darbepoetin alfa), Enbrel@ (etanercept), EPOGEN@ (Epoetin alfa), Neulasta® (pegfilgrastim),
NEUPOGEN® (Filgrastim), Nplate® (romiplostim), Prolia® (denosumab), Sensipar® (cinacal-
cet), Vectibix® (panitumumab), and XGEVA® (denosumab) [16].
Amgen supports the therapeutics it develops and markets through activities that include the
following: process development, clinical manufacturing, bulk protein manufacturing, formulation
/ fill / finish, distribution, and quality and regulatory compliance. It has one clinical manufacturing
facility located in Thousand Oaks, CA and several commercial manufacturing sites located in the
United States, Europe, and South America [17].
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Chapter 3. Innovation - Decision-Making and
Implementation
Due to the factors discussed in Section 2.2, companies need to constantly innovate and therefore
introduce new technologies into their production methods to stay competitive. This often requires
numerous decision makers within the company. In order to suggest improvements to Amgen's
decision-making processes, we interviewed Amgen stakeholders to understand its current decision-
making methods and interviewed executives at similarly situated companies to benchmark current
practices. Then, various decision-making methods were researched for implementation in order
to alleviate issues with and improve the outcome of Amgen's current decision-making processes.
Once a technology is selected for implementation, the implementation process needs to be robust
enough such that the implementation is successful. This thesis focuses solely on the decision-
making process and some thoughts on implementation are discussed in the conclusion.
3.1 Benchmarking Current Practices
Stakeholders in Amgen's process and product engineering, process and product development, clin-
ical operations, corporate manufacturing, and finance departments were interviewed to understand
Amgen's current processes for making technology implementation decisions. Typically a success-
ful technology starts in research and makes its way to process development, the pilot plant, clinical
manufacturing, and finally commercial manufacturing. At each step along the way, executives or
a committee decides whether to keep investing in the technology. They usually evaluate the tech-
nology with a business case and net present value (NPV) financial analysis. The business case
describes the objective of the technology and presents the pros and cons of implementation while
the financial analysis takes a discounted cash flow using a standard discount rate. Some Amgen
executives feel that a NPV analysis is easily biased by the analyzer's assumptions to support any
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desired outcome. In the early 2000s, Amgen explored using decision analysis, which includes a
real options financial model to understand the expected value of a new technology. However, after
using decision analysis for a few years, they found the process to be too cumbersome; therefore,
they reverted to using net present value since it was simple and well understood by executives.
In addition, when groups have had to select one out of various technologies, they have some-
times used Kepner-Tregoe (KT) analysis. KT analysis involves a group meeting with a facilitator
to select the criteria around which to evaluate options, assigning weights to the criteria, and then
ranking the options for each criterion. The sum-product of the weights with the rankings gives
a ranking of the best option to select. However, this process is not well-suited to many of the
decisions that Amgen needs to make for the following reasons:
" It is incapable of handling both subjective and objective criteria in a simple manner.
" It is subject to bias from the entire group picking the weights together in the same room.
" The "boss" may influence choices as stakeholders try to please him/her.
" Group dynamics such as an "800-lb gorilla" and shy participants affect the outcome.
" It requires a facilitator and the decision-makers to meet together at the same time.
Three executives from other large biotechnology or pharmaceutical companies were also inter-
viewed to understand their company's processes for innovating and implementing new technology.
They mentioned that new technology often gets propagated bottom-up from scientists. Scientists
may get excited about a certain technology that they discover at a conference or read in a scientific
journal article and then they propagate it through their organization. In addition, sometimes new
technologies are developed based on scientific grass-roots idea generation. Finally, there are also
top-down technology initiatives from executives who are looking at reducing risk or improving
another measure.
Since there is much business pressure to develop new products quickly, one company develops
new technologies as part of their process development due to limited resources. However, they
think this is risky and increases the timeline to introduce a new technology. Another company
said they used to use real options in order to analyze technology improvement options, but it was
controversial so they abandoned that method and instead now use return on investment (ROI) to
make decisions. The financial analysis for return on an investment was not very rigorous and
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they felt they were good at estimating costs. The third company said that they have a technology
council that meets monthly to go over new technology options along with opinions from various
departments. The council acts as an advocate for new technologies with management.
No matter what method each company uses to discuss, evaluate, or introduce technologies, each
felt that it was important to connect research and development, operations, strategy, and finance
when making decisions. One company believed that technology development should be inde-
pendent from process development for producing a new biologic or pharmaceutical drug, thereby
taking technology development out of the critical path of producing new molecules. The result
from interviewing the executives was the realization that there is not currently a gold standard for
technology assessment and implementation.
3.2 Decision-Making
Decision-making is a complex process as there are often various inputs into the process and the
outcome is usually of critical importance. Yet, decision-making is difficult because much uncer-
tainty usually exists around the inputs into the process and there are numerous ways to look at
a single problem. Many types of decision-making and technology assessment methods and tools
exist as shown in Table 2. These tools typically fall into the areas of economics, decision analysis,
group decision support systems, systems engineering/systems analysis, technological forecasting,
information monitoring, technical performance assessment, risk assessment, market analysis, and
externalities/impact analysis.
Christensen et al. discuss in [19] how three typical financial analysis tools can hurt innovation
in companies. These tools are the discounted cash flow and net present value, fixed and sunk
cost considerations, and emphasis on earnings per share and looking only at the impact to short-
term financials. In regards to discounted cash flow and NPV, they say that innovators commonly
make two errors that promote anti-innovation. First, that the base case against which a project is
compared is the current health of the company and the belief that it will extend indefinitely into
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Table 2: Technology assessment toolkit for managing
Taken from [18].
technology in the globally competitive enterprise.
Economic Analysis
Cost/Benefit Analysis
Cost-Effectiveness Analysis
Lifecycle Cost Assessment (LCA)
Return on Investment (ROI)
Net Present Value (NPV)
Internal Rate of Return (IRR)
Breakeven Point Analysis
Payback Period Analysis
Residual income
Total Savings
Increasing Returns Analysis
Decision Analysis
MultiCriteria Decision Making
Multiattribute Utility Theory
Scoring
Group Decision Support Systems (GDSS)
Delphi/Group Delphi
Analytic Hierarchy Process (AHP)
Q-sort
Decision Trees
Fuzzy Logic
Systems Engineering/Systems Analysis
Technology System Studies
System Dynamics
Simulation Modelling and Analysis
Project Management Techniques
System Optimization Techniques
Linear, Integer, and Non-linear Programming
Technology Portfolio Analysis
Technological Forecasting
S-Curve Analysis
Delphi/AHP/Q-Sort
R&D Researcher Hazard Rate Analysis
Trend Extrapolation
Correlation and Causal Methods
Probabilistic Methods
Information Monitoring
Electronic Databases
Internet
Technical/Scientific Literature Reviews
Patent Searches
Technical Performance Assessment
Statistical Analysis
Bayesian Confidence Profile Analysis
Surveys/Questionnaires
Trial Use Periods
Beta Testing
Technology Decomposition Theory
S-Curve Analysis
Human Factors Analysis
Ergonomics Studies
Ease-of-Use Studies
Outcomes Research
Risk Assessment
Simulation Modeling and Analysis
Probabilistic Risk Assessment
Environment, Health, and Safety Studies
Risk-based Decision Trees
Litigation Risk Assessment
Market Analysis
Fusion Method
Market Push/Pull Analysis
Surveys/Questionnaires
S-Curve Analysis
Externalities/Impact Analysis
Externalities Analysis
Social Impact Analysis
Political Impact Analysis
Environmental Impact Analysis
Ethical issues Analysis
Cultural impact Analysis
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the future. Instead, it is more probable that there will be a nonlinear decline in performance. They
reference that this is typically called Parmenides' Fallacy. Second, they discuss how discounted
cash flows can suffer from estimation errors because the impact of future investments are hard to
predict beyond a few years out. In regards to fixed and sunk costs, they argue that the idea of
having to choose between full-cost and marginal-cost options does not allow a company to make
the same decisions that a new entrant might make and thus the company does not make a decision
for the future. Finally, they note that many executives are incentivized to think about the short-term
financial costs rather than looking at the long-term picture, which may cause innovation projects to
not be implemented that in fact should be for the long-term benefit of the company. The paper also
discusses how the stage-gate approval process for technology focuses too much on the numbers
that are based on many assumptions and they instead suggest using a discovery-driven planning
process [19].
Once a technology assessment has finished and a technology option is selected, then the tech-
nology must actually be implemented. Klein and Knight discuss several issues with technology
implementation and suggest ways to improve technology implementation success [20]. They cite
that there are six major reasons for difficult technology implementation [20]:
" Many innovations are unreliable and imperfectly designed.
* Many innovations require would-be users to acquire new technical knowledge and skills.
" The decision to adopt and implement an innovation is typically made by those higher in the
hierarchy than the innovation's targeted users.
" Many team and organizational innovations require individuals to change their roles, routines,
and norms.
" Implementation is time consuming and expensive.
" Organizations are a stabilizing force.
This results in "observers estimat[ing] that nearly 50% or more of attempts to implement major
technological and administrative changes end in failure [20]."
Based on the literature above, I believe Amgen should augment its net present value financial
approach with more holistic measures that will not let it fall into the traps that Christensen dis-
cusses. Meyers et al. say that "as reasoned by experts, some innovations do not result in desired
benefits because of a mismatch between the buyer's strategic goals and the innovation's implemen-
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tation and results...however, when the supplier keeps an eye on the full range of factors-technical
and otherwise-successful implementation is more likely [21]." In addition, the technology inno-
vation that Amgen implements often impacts numerous areas and therefore its decision-making
tools should handle information from many people so that those whom the technology affects are
involved in the decision-making process. Therefore, out of the above decision-making methods,
the Analytic Hierarchy Process was selected for its robust behavior and is discussed in Section 4.1.
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Chapter 4. Framework
As discussed earlier, Amgen typically utilizes a business case and NPV analysis or Kepner-Tregoe
analysis in order to make technology decisions. Yet, an objective, standard decision-making pro-
cess would be highly beneficial for implementing new technologies. There are numerous decision-
making approaches as discussed in Section 3.2 and Amgen needed a new approach that was objec-
tive, robust, simple, easy-to-use, easy-to-understand, quick, and that easily allowed global, group
collaboration. Due to these factors, the Analytic Hierarchy Process was selected as the decision-
making method in a simple framework shown in Figure 9.
Process for Evaluating Technology Options
Figure 9: Assessment Process for Technology Decisions. The process starts with identifying the options
amongst which the decision needs to be made. Then the criteria are selected in order to create
the AHP hierarchy. Pair-wise comparisons are performed on the criteria and options. Finally,
the group meets to discuss the results and evaluate the output with sensitivity analysis.
4.1 The Analytic Hierarchy Process (AHP)
The Analytic Hierarchy Process (AHP) was developed by Thomas Saaty in the 1970s as a novel
group decision-making method [22]. There are many literature citations where it has been used for
technology implementation decisions [23, 24, 25, 26, 27, 28, 29, 30]. The process involves partic-
ipants making pair-wise comparisons amongst criteria in order to determine the correct weighting
of various factors. First, the stakeholders must identify the various options that need to be priori-
tized or selected against. Next, the criteria must be selected in which to evaluate the various options
against. These criteria are setup in a hierarchy from basic to specific as shown in Figure 10.
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Example Analytic Hierarchy Process (AHP)
Subjective Criteria
i.e. Risk, Quality, Flexibility
(2) (3) (1)
Figure 10: Example Analytic Hierarchy Process. At the top of the hierarchy is the decision - select a
technology option. Beneath the decision are various criteria, subjective criteria are denoted
on the left and objective criteria are denoted on the right. The criteria in the yellow boxes are
criteria with sub-criteria and these are not evaluated against the options. The criteria in blue
boxes represent covering criteria and these are evaluated against the options. At the bottom of
the hierarchy in the green boxes are the options. Beneath each criteria box is the local weight of
the given criteria (each row of the hierarchy sums to 1). Beneath each option box is the result of
the sum product of the criteria weights and option weights. This value gives the ranking of the
options. In this example, the ranking is Option 3, Option 1, Option 2.
The hierarchy is composed of both covering criteria and regular criteria. The covering criteria
are the criteria without any sub-criteria and the criteria against which the options are evaluated.
The regular criteria are all criteria that are not covering criteria and they are used to determine
the overall weighting of the covering criteria. The AHP process involves stakeholders individually
making pair-wise comparisons amongst criteria on the same row and then comparisons of the
options against the covering criteria. Weights are assigned based on the comparisons and then the
output, a ranking, is based on the sum-product of the criteria weights and the comparisons between
the options and covering criteria. Typically, the fundamental scale for pairwise comparisons as
shown in Table 3 is utilized for the comparisons. However, it is also possible to use words such
as "equal," "moderate," "strong," "very strong," and "extreme." Another option is to use a graphic
representation such as area or volume of an object to compare two items.
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Table 3: The Fundamental Scale for Pairwise Comparisons. The scale commonly used for pairwise com-
parisons in AHP Adapted from [22, 31].
Intensity of Definition Explanation
Importance
1 Equal Importance Two elements contribute equally to the objective
3 Moderate Importance Experience and judgment moderately favor one element over
another
5 Strong Importance Experience and judgment strongly favor one element over an-
other
One element is favored very strongly over another; its domi-
nance is demonstrated in practice
9 Extreme Importance The evidence favoring one element over another is of the
highest possible order of affirmation
Intensities of 2, 4, 6, and 8 can be used to express intermediate values. Intensities of 1.1, 1.2, 1.3, etc.
can be used for elements that are very close in importance.
The weights for the criteria or options are derived from the comparisons by entering them on
a matrix as shown below. When the equation Aw = nw is solved, the value for n represents the
principal eigenvalue for the matrix A with w being the eigenvector for matrix A. The values in the
eigenvector represent the weights for the respective criteria [22].
A1  A 2  --- An
A 1  wI/w1 w1/w2 --- WI/wn W1 1
A 2  W2/W1 w2/w2 ... W2/Wn W2 W2
An Wn/w1 wn/w2 --- wn/Wn Wn Wn
For example, we can take a 3x3 matrix as shown below and calculate the eigenvector. First, the
product of the values in each row is calculated giving 0.5, 0.125, and 16 from top to bottom of the
matrix. Then the nth root of these values is determined. Since this is third order matrix, the third
root of the product of each row is taken giving 0.7937, 0.5, and 2.5198 from top to bottom of the
matrix. Finally, the eigenvector is determined by taking the third root terms and dividing them by
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the sum of the third root values, which equals 0.7937 +0.5 + 2.5198 = 3.8135. So the eigenvector
is 0.2081, 0.1311, 0.6607 from top to bottom of the matrix. Thus, the A1 factor has a weight of
20.81%, the A2 factor has a weight of 13.11%, and the A3 factor has a weight of 66.07%.
Ai A2 A3
A1  1 2 0.25
A2  0.5 1 0.25
A3  4 4 1
Only those individuals that have specific knowledge about a given branch of the criteria or the
options in the hierarchy need to do comparisons. Thus, AHP is flexible such that only subject mat-
ter experts determine the weightings of criteria and options. Once the weights are derived for each
individual's comparisons, the weights can be combined to determine the overall group's ranking
of the options. Therefore, it is possible to combine different subsets of individuals participating
in an AHP analysis to determine how a certain department or group of individuals would make
the decision if they were the sole deciders. It is also possible to weight certain individuals more
strongly than others, for example, to give the decision-maker two or three times the weight of other
individuals when combining the scores.
4.1.1 Consistency
Since participants make multiple pair-wise comparisons amongst the criteria on a given branch
and level of the hierarchy, it is important to ensure that the participant makes the comparisons in
a consistent manner. For example, it is not logical to say that A is better than B, B is better than
C, and then C is better than A. Instead, to be consistent, A should be better than C. Therefore, it
is necessary to calculate a consistency score that the participants and project manager can use to
ensure both that the participant is thinking about their comparisons and that it is done in a logical
manner.
Since the participants do not just make a binary comparison (participants can say A is much
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better than B or A is slightly better than B), then the process needs to allow for some inconsis-
tency. The method proposed by Saaty involves determining a consistency index (CI) that equals
(Amx - n) / (n - 1), where n represents the principal eigenvalue of the matrix A above. The con-
sistency index is then "compared with the same index obtained as an average over a large number
of reciprocal matrices of the same order whose entries are random. If the ratio (called the consis-
tency ratio CR) of CI to that from random matrices is significantly small (carefully specified to be
about 10% or less), we accept the estimate of w. Otherwise, we attempt to improve consistency
[22]." If a set of comparisons are completely consistent then Amax = n.
4.1.2 Criteria
One of the major benefits of the analytic hierarchy process is that it can include both subjective
and objective criteria for the options to be compared against. AHP is good for subjective criteria
because someone can usually easily make a comparison of one item against another on a scale.
However, AHP is also good for objective criteria because an objective item can easily be mapped
to the fundamental scale for pairwise comparisons. For example, if we were comparing two cars
against cost, one could take the ratio of the costs in order to select how much better one car is over
the other. Another method with a budget could be to compare the cost to the budget and rank based
on the ratio of how much the cost deviates from the budget. This method can be adapted for many
situations involving objective data.
4.1.3 Adaptations
Numerous adaptations have been suggested and implemented since AHP was first described and
introduced. These include methods to introduce fuzzy logic around the comparisons such that
greater uncertainty can be taken into account [29]. A similar process called the Analytic Hierarchy
Network (ANP) builds on AHP by allowing feedback loops instead of a simple hierarchy [29].
Advancements have been suggested for calculating a consistency score and the cut-off for when a
matrix is consistent enough to be accepted [32]. Finally, improvements have been suggested for the
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calculation of weights for the criteria, especially for incomplete matrices, which are comparison
matrices where the participant does not make every pair-wise comparison possible [33].
4.1.4 Criticisms
The major negative aspect of AHP is that it can suffer from rank reversal. Rank reversal can occur
if an option is added to the hierarchy after an analysis is performed. The addition of the extra
option could cause some of the rankings from the previous analysis to reverse instead of the new
option just being inserted into the same ordered ranking. This can be a slight issue in prioritization
where the objective is to prioritize many projects or options for importance. However, in the case
where a single option is being chosen for implementation, rank reversal will have little impact.
4.2 Commercial Software Implementation
Several previous theses discussed creating and implementing decision-making tools in Microsoft
Excel at various companies [34, 35, 36]. However, some of these companies have noted that adop-
tion and maintenance of such tools was difficult after the project period. Therefore, in order to im-
prove the usability and sustainability of a new decision-making process for Amgen, several com-
mercial decision-making tools that implement AHP were investigated. The software researched
were EC 11.5 and ComparionTM Suite by Expert Choice@ (http://www.expertchoice.com), Deci-
sion Lens 3 by Decision Lens, Inc. (http://www.decisionlens.com), and MindDecider Team by
MindDecider (http://www.minddecider.com).
The software by Expert Choice@ was chosen after examining the various features, availability,
support, price, and implementation offered by the three companies. Decision Lens only offered a
consulting model that required a consulting contract along with the software. MindDecider lacks
the usability and support I sought as it is based outside the United States and did not offer a
web-based solution. In addition, it has a unique user interface that has no menus and requires a
lot of mouse right-clicks to select options. The software made by Expert Choice® has a typical
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user interface, has excellent documentation and support, and is provided in two versions that were
well-suited for the project period and then for implementation throughout Amgen after the project
period. Expert Choice only implemented the base version of AHP without any adaptations. Since
this was the first implementation of AHP throughout Amgen, the goal was to use the simplest
method that met the objective, which the base version of AHP does.
The two versions of software made by Expert Choice are a desktop version called EC 11.5 as
shown in Figure 11 and a web-based version called ComparionTM as shown in Figure 12. We used
the desktop version of the software during the project due to the short time duration of the project
and the time required to install the web-based version on internal Amgen servers. However, be-
cause the web-based version has greater usability for projects that involve many people in multiple
locations, that is the version recommended for use at Amgen beyond the project period. Because of
the limitations in the desktop version for use with people in multiple locations, I created a Microsft
Excel worksheet survey with slider bars that I sent around to participants in order to record their
feedback to the AHP comparisons as shown in Figure 13. The survey results were then inputted
into the Expert Choice desktop software.
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Figure 11: Screenshot of Expert Choice EC 11.5 Desktop software.
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Figure 13: Screenshot of Microsoft Excel Survey for AHP Analysis. A Microsoft Excel spreadsheet was
created for stakeholders to input their pair-wise comparisons of criteria and alternatives. The
results were then input into the Expert Choice EC11.5 Desktop software.
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Chapter 5. Case Studies
Several case studies were undertaken in order to test out the framework and decsion-making pro-
cess. The first case study investigated the use of Expert Choice software for AHP analysis as
compared to a Microsoft Excel-based AHP implementation performed two years prior with the
eData Infrastructure Technology (EDIT) Forum. The second case study looked at using AHP for
a project selection decision as compared to the typical method of using a business case and net
present value financial analysis. We modeled the project in AHP concurrently with the typical
analysis in order to compare the outcome. Finally, the third case study used AHP to make a deci-
sion on an issue de novo that had had five previous analyses performed without an actual decision
being made and implemented.
5.1 eData Infrastructure Technology Project Prioritization
At the end of 2010, Amgen's eDIT Forum tried to prioritize projects that they had on their agenda
for the following year. In order to prioritize the projects, they built a home-grown implementation
of AHP in Microsoft Excel. The 12 stakeholders on the forum analyzed the criteria in the ana-
lytic hierarchy as shown in Figure 14 and the 14 projects against the criteria. The project manager
implemented AHP in Excel by having participants make pair-wise comparisons in a long list that
required the participant to select A or B along with a number for the relative strength of the com-
parison for each row. The scale used was the typical AHP scale as shown in Table 3 in Section 4.1.
Once the spreadsheet with the relevant criteria was created, the project manager and participants
e-mailed it back and forth. The Excel spreadsheets used in the initial project had to be revised
several times due to programming errors that can arise in a home-grown project. A survey of the
participants was performed at the end of the analysis; they found the process with Excel to be too
laborious and time-consuming.
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Figure 14: AHP Hierarchy for eDIT Project Prioritization. The yellow box denotes the objective of the
hierarchy criteria. The grey boxes represent general criteria whose weightings are derived from
the weighting of the more specific covering criteria shown in the blue boxes.
We took the data from the Excel analysis and input it into Expert Choice Desktop 11.5 in order
to compare factors such as time, management, multiple user support, data, and others between
the two software packages. As the data was input into Expert Choice, we noticed some minor
mistakes in calculations that had not been caught and fixed in the final Excel analysis performed
the previous year. While the desktop version of Expert Choice was used for the analysis due to
time and money constraints, the benefits would be extendable to the web-based version of Expert
Choice that Amgen would use in the future. The differences between Excel and Expert Choice
were then discussed with the project manager.
The Expert Choice software was deemed superior to Excel based on five categories as summa-
rized in Table 4. Expert Choice allows a user to easily create any new hierarchy with a few clicks of
the mouse compared to the required manual setup of many cells with complex calculations within
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Excel for each new decision hierarchy. Expert Choice also eliminates any possible errors from ty-
pos or wrong cell references that can occur in the manual setup process in Excel. The desktop and
web-based version of Expert Choice stores everyone's responses in one place without the need to
consolidate individual responses as is required with Excel. With Excel, the project manager needs
to e-mail spreadsheets back and forth with participants and keep track of each person's spreadsheet
responses. The web-based version of Expert Choice handles multiple users in an easy manner by
sending e-mails to participants allowing them to go to a website to make their pair-wise compar-
isons rather than the project manager sending unique instances of spreadsheets to users requiring
them to go row-by-row to record their responses with Excel. The Expert Choice software has nu-
merous built-in tools to analyze the results including several different sensitivity analysis graphs
on the weights of the criteria, checks on the consistency of people's responses, and the ability to
compare each person's response with each other. The Microsoft Excel version has no sensitivity
analysis or other methods to compare the responses of individuals to each other. Since Expert
Choice is commercial software designed for AHP analysis, it comes with detailed documentation
on how to use the software and perform analyses. It also includes professional technical support.
A user-created Excel version has no such documentation and requires the programmer who made
the spreadsheets to manually comment and provide on-going support. Finally, the only category
in which Excel is better than Expert Choice for AHP analysis is the availability of the software.
Every user within Amgen has Microsoft Excel on their computers for numerous tasks and is there-
fore considered free. However, the web-based version of Expert Choice requires a yearly license
that is on the order of tens of thousands of dollars.
In addition to comparing the identical processes with different software packages, we also
analyzed features that Expert Choice contains that the Excel-programmed AHP did not. In the
eDIT analysis the stakeholders were required to make every possible comparison among pairs of
criteria. This resulted in the complaint from participants that the process was too time-consuming.
However, Expert Choice has several options that can reduce the number of comparisons necessary
in order to save time when there are either a large number of criteria, a large number of options, or
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both. Furthermore, Expert Choice has built-in functions that allow a utility, maximum, or minimum
function to be used when comparing objective values. Expert Choice also contains several built-in
sensitivity analyses that allow for the dynamic adjustment of criteria weights that can be used to
identify weighting cutoffs to shift a certain project's ranking. Finally, Expert Choice has an add-
on called Resource Aligner that allows a cost-benefit selection of projects to take place for cases
where AHP is being used for project prioritization.
Table 4: Excel vs. Expert Choice Comparison for AHP. The italicized areas were deemed better for the
given software approach. Expert Choice is better in every category except availability.
Microsoft Excel® Expert Choice@
Time intensive setup and administration, easy setup, built-in calculations reduces
error-prone errors
Management spreadsheets, e-mail, time intensive web-based, time-saving
Multiple User Support tedious built-in (web-based version only)
Data manually processed built-in synthesis and sensitivity analysis
Documentation none provided
Availability free yearly license
Based on the comparison between Excel and Expert Choice, management made the decision
to use Expert Choice for future decision-making processes involving AHP. While Expert Choice
requires a yearly fee compared to Excel, its use will allow for easy setup of analyses that does
not require a programmer and it will be more sustainable due to its documentation and technical
support availability.
5.2 Clinical Manufacturing Building Upgrade Selection
Amgen needed to update its master plan for its formulate / fill / finish clinical manufacturing facility
in Thousand Oaks, CA. The goal of the project was to select a facility upgrade plan that would bring
clinical manufacturing into technology alignment with commercial manufacturing, allow for the
testing of future technologies, reduce costs and improve economics, enable more rapid response
to clinical demands, mitigate risks, and ensure lifecycle support for Amgen's products. Many of
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drivers reasons overlap with the factors for change in the industry discussed in Section 2.2. The
main method to accomplish the goal involved selecting a plan to upgrade the technology used to
formulate the clinical drug substance and fill vials and syringes. With the help of an engineering
consulting firm, plant management identified the three options listed in Table 5 of which they
needed to select the best one.
Table 5: Clinical Manufacturing Upgrade Options. Three options were evaluated in order to determine the
best path forward for Amgen's clinical manufacturing facility. The description details have been
left out to protect confidential information.
Description Location
Do Nothing Current State Current Building
Option 1 Adds Catch-up Technology, Maintains Legacy Ca- Minor Building Renovation
pabilities, Prepares for Future Expansion into Adjacent Building
Option 2 Future Capabilities, Maintains Legacy Capabilities Expansion into Adjacent Building
The main technologies suggested for implementation in option 1 and option 2 were restricted
access barrier systems (RABS), isolators, and automated inspection. Until recently, the current
standard for filling vials and syringes was to do so in a class 100 / ISO 5 cleanroom (a maximum
of 100 particles of size 0.5 pm or larger per cubic foot of air) with restrictions around the movement
of operators. However, newer technology such as RABS and isolators can be more aseptic as they
are more contained. An isolator is a large machine with a pressurized, aseptic environment within
it that allows for the filling of vials and syringes without any human interaction. In addition,
the machine can be fully sterilized with vaporous hydrogen peroxide (VHP). RABS are more
exposed to the air in a room and generally require manual cleaning. These newer technologies
provide numerous benefits over a standard cleanroom and the FDA and other regulatory agencies
are starting to expect pharmaceutical companies to upgrade their facilities.
Along with newer filling equipment, regulatory agencies want to ensure that all vials and sy-
ringes are particle free so that only product is injected into patients. Currently, the clinical man-
ufacturing facility uses manual inspections to ensure product reaches patients particle-free while
commercial manufacturing facilities use a combination of manual and automated inspection. Au-
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tomated inspection allows for an extra inspection step and ensures that no product is delivered to
patients with any glass fragments, protein aggregates, or other issues.
The project team of 12 stakeholders came from a wide array of departments such as finance,
project management, facilities engineering, quality, clinical manufacturing, corporate manufac-
turing, process and product development, and process and product engineering. The group met
to develop the AHP first and second level criteria hierarchy as shown in Figure 15 based on the
project description and goals.
Figure 15: AHP Hierarchy for Clinical Manufacturing Upgrade Selection. The yellow box denotes the
objective of the hierarchy criteria. The grey boxes represent general criteria whose weightings
are derived from the weighting of the more specific covering criteria shown in the blue boxes.
A survey was sent to each of the 12 stakeholders for them to make pair-wise comparisons
amongst the criteria in order to obtain the weighting for each criteria. Participants were instructed
to only compare the criteria in which they felt knowledgeable and they did so using the funda-
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mental scale for pairwise comparisons. The results from the survey were compiled and input into
the Expert Choice software. Then the stakeholders who had the most detailed knowledge about
each of the options met to compare the options against the covering criteria. This included the
plant manager / executive director, plant director, project engineer, and project manager. As there
is much uncertainty about the future, many of the comparisons, except for cost, required the stake-
holders to make subjective comparisons. All the comparison results were input into Expert Choice
with the results shown in Figure 16.
Combined Results (Overall)
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Figure 16: Overall Results from Clinical Manufacturing Upgrade Selection AHP Analysis. The criteria
weights (grey bars) resulted from the combined pair-wise comparisons of 12 stakeholders. The
option weights (lines) for each criteria category were derived from the combined pair-wise com-
parisons of the four stakeholders with the most knowledge of the options.
The pair-wise comparisons of the criteria resulted in technology having the highest impact,
followed by risk after implementation, risk during implementation, cost, and space. The pair-wise
comparisons resulted in "do nothing" being the highest rated option for space and risk during
implementation. Option 1 was the highest rated for risk after implementation while option 2 was
highest rated for technology and cost. The overall combination of the criteria weights and option
weights resulted in option 2 being ranked slightly higher than option 1 with "do nothing" ranked
last. Since the overall results between option 1 and option 2 were so close, it may help to look
deeper into each criteria category to understand how each option was weighed in regards to the
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covering criteria. Graphs representing the criteria weights and option weights for the second level
criteria are shown in Figure 17.
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Figure 17: Clinical Manufacturing Upgrade Selection Level 2 Criteria Weights from AHP Analysis. The
criteria weights (grey bars) resulted from the combined pair-wise comparisons of 12 stakehold-
ers. The option weights (lines)for each criteria category were derived from the combined pair-
wise comparisons of the four stakeholders with the most knowledge of the options.
Beyond being able to see the combined results of all the stakeholders, one of the advantages of
AHP is that the project manager and decision makers can analyze the responses from the individual
participants. The results from four of the individuals that took part in the clinical manufacturing
upgrade selection analysis are shown in Figure 18. The decision-makers can thus take the back-
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ground of an individual into account to see what the outcome would have been if they were the
sole decision-maker based on their department, geography, or some other trait. If a true outlier
is observed, that person can be removed from the overall analysis to see how the overall results
would change. Thus, the decision-maker can ensure the right decision is made between two very
close options.
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Figure 18: Example Individual Results from Clinical Manufacturing Upgrade Selection AHP Analysis. The
outcome of the analysis for person 1, person 2, and person 4 ranked option 2 as the best alter-
native. The outcome of the analysis for person 3 ranked option 1 as the best alternative. The
relative difference between the three options was lessforperson 2 than for the other individuals.
The typical decision process (business case and NPV) was performed simultaneously with the
AHP analysis. The typical analysis identified option 1 as the best plan for the future. As is the case
with traditional decision-making, the plant manager had identified option 1 as the best plan before
the analysis was complete based on his "gut instinct." Therefore, management initially proposed
option 1 to senior management as the best option. However, the AHP analysis showed that overall
option 1 and option 2 are very similar and that perhaps option 2 would be best depending on
the priorities of senior management and basically the tradeoff of future technology and risk after
implementation.
The clinical manufacturing upgrade project was an excellent case to test the AHP decision-
making process. The stakeholders had an idea of what they wanted to accomplish along with
several options that would satisfy their goals to varying degrees. AHP allowed the stakeholders to
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clearly define and objectively assess the correct weightings of the objective and subjective criteria
while taking into account the opinions of many individuals. The outcome showed the typical anal-
ysis was correct, but that either option 1 or option 2 could be justified depending on the preference
of one criterion over another. This helped ensure management made the right decision.
5.3 Drug Substance Storage Container Technology Selection
Amgen stores its drug substance material in a frozen state after the purification process but before
the formulate / fill / finish process. They currently use two container technologies, plastic carboys
and steel cryovessels as shown in Figure 19. Amgen had performed five studies since 2005 in order
to select a standard container technology in which to store its drug substance. Four of the studies
suggested carboys while the most recent study suggested cryovessels; each study only looked at
a single aspect of the technologies such as their impact on costs, supply chain risk, freeze/thaw
rate, or throughput. Since each analysis focused on a narrow effect of the technology, the leader
of each study could not achieve buy-in from management on the correct container technology and
thus another study was requested. In 2011, management wanted a holistic look at the technologies
so it could finally make a decision and standardize its processes. AHP is a perfect tool for such an
analysis.
(a) Carboy (b) CryoVessel
Figure 19: Carboy and Cryovessel
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The project manager requested stakeholders from diverse departments such as finance, supply
chain, global strategic sourcing, quality, clinical manufacturing, corporate manufacturing, process
and product development, and process and product engineering. The stakeholders also represented
the various manufacturing locations such as Rhode Island, Puerto Rico, California, Colorado, Ire-
land, and contract manufacturing sites. The group was composed of 14 individuals and it met over
several weeks to develop the first and second level criteria hierarchy shown in Figure 20 and the
third level criteria as listed in Tables 6-11 in Appendix A. A pipeline biologic drug was used as a
model molecule for the mathematical analysis of throughput effects.
Figure 20: AHP Hierarchy for Drug Substance Container Selection. The yellow box denotes the objective of
the hierarchy criteria. The grey boxes represent general criteria whose weightings are derived
from the weighting of the more specific covering criteria, which are shown in Tables 6-11 in
Appendix A.
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There are many characteristics of a drug substance container that differ between the plastic car-
boys and stainless steel cryovessels as shown in the hierarchy. The plastic carboys are made from
resins that need to be tested for leachable and extractable data to ensure that the plastic material
does not affect the biologic product. In addition, the plastic material needs to be checked to ensure
that there are no particles leftover from the vessel production process. The stainless steel cryoves-
sels do not have these issues since the material is inert and does not shed. In addition, the vessels
are available from manufacturers in different range of volumes. Carboys are smaller (typically
10-20 liters) and thus more would be needed for a large production volume whereas cryovessels
are larger (typically 200 liters). Carboys are relatively cheap and single-use whereas cryovessels
are expensive to procure and last about ten years, which requires cleaning and maintenance. The
various characteristics of the vessels also impact the supply chain and logistics through differences
in how they affect transportation, storage, capacity, delivery, and risk.
A survey was sent to each of the 14 stakeholders for them to make pair-wise comparisons
amongst the criteria in order to obtain the weighting for each criterion. Participants were in-
structed to only compare the criteria in which they felt knowledgeable and they did so using the
fundamental scale for pairwise comparisons. The results from the survey were compiled and input
into the Expert Choice software. The subject matter experts in each area acquired any objective
data that could be used in the analysis. The objective data was then compiled and sent out to the
14 stakeholders along with a survey for them to make pair-wise comparisons of the options against
the covering criteria. All the comparison results were input into Expert Choice with the results
shown in Figure 21.
The results showed that in every major level criteria category except logistics that the stainless
steel cryovessels are strongly preferred over the plastic carboys. This resulted in the overall pref-
erence of the cryovessels as compared to carboys in the ratio of two to one. However, when this
recommendation was presented to senior management, they did not necessarily believe the result.
Since various analyses for this decision have been on-going for over five years, many managers
had preconceived notions or "gut instinct" on which container technology should be selected as
56
Combined Results (Overall)
80%
70%
* 60%
0%
4 0%
M 30%
20%
10%
0%
Finance Supply Quality Drug Drug Product Logistics Overall
Substance Fill Process
Process
- Carboys - Cryovessels
Figure 21: Overall Results from Drug Substance Container AHP Analysis. The criteria weights (grey bars)
resulted from the combined pair-wise comparisons of 14 stakeholders. The option weights (lines)
for each criteria category were derived from the combined pair-wise comparisons of the four
stakeholders with the most knowledge of the options.
the standard. Since AHP analysis was new to senior management, there did not exist much trust
in the process and therefore management requested that a typical business case and NPV analysis
be performed that included all the criteria included in the AHP analysis. This analysis is currently
on-going as of spring 2012.
Since AHP is a new decision-making tool, there will be barriers that need to be overcome
in order to achieve buy-in from management. Performing an AHP analysis along with a typical
analysis, as was done with the Clinical Manufacturing Upgrade Project, will allow management
to compare a process they are familiar with against a new process. Thus, over time they can learn
to trust the result of the AHP method and see the value that it provides. Now, there will always
be the issue where a key decision-maker already has in mind a result and that person just wants
any analysis to confirm and match the pre-determined result. While a decision-maker may have
significant experience in a certain area, it is important to step back and look at a scenario in an
objective manner. That is one of the purposes of the AHP process. Thus, incentives may be
required for managers to use the AHP process for more informed decision-making.
57
= I-E1411
This page intentionally left blank.
58
Chapter 6. Conclusion and Recommendations
6.1 Conclusion
Economic, regulatory, and other factors are spurring innovation in pharmaceutical manufacturing
technologies. Changes in both small and macromolecule pharmaceutical manufacturing requires
companies to make decisions about which technologies to implement and when and where to
implement them. An objective decision-making approach can help ensure the correct decisions are
made, but the process is difficult because decision-makers prefer quick, simple analyses and there
is often a lot of uncertainty in predicting the long-term benefits and risks of new technology.
Therefore, in this thesis the Analytic Hierarchy Process was described as a method that allows
both objective and subjective factors to be taken into account in decision-making. The process
eliminates many of issues with traditional decision-making approaches and allows a manager to
understand the input from many individuals on a decision-making team. A case study was per-
formed to test the benefits of commercial software and two case studies were performed to assess
AHP as a decision-making process. The results from the case studies showed that using Expert
Choice@ is a sustainable approach to decision-making for large teams across different geographies
from different departments. The AHP analysis allowed managers to understand why a certain de-
cision is preferable over another and perform sensitivity analysis to further understand the results.
Making decisions is difficult and it is likely that no method is applicable for every decision that
needs to be made. However, using the Analytic Hierarchy Process is one step in the right direction
towards making better, more objective decisions. Therefore, companies need to frequently evaluate
their decision-making approaches and adapt their methods to the right situation in order to ensure
all voices are heard and the right information is taken into account.
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6.2 Recommendations
Amgen should continue to use the AHP decision-making method with Expert Choice@ for their
future technology decisions. In order to do so, Amgen may want to socialize the approach and
continue getting buy-in from further case studies with other departments, including those outside
of manufacturing. In addition, Amgen may want to implement AHP as a standard decision-making
platform while advertising its benefits throughout its departments. AHP is a robust decision-
making process that can help managers make objective decisions on any topic. For the case studies
in this thesis, the desktop version of Expert Choice was utilized in order to complete the studies in
the time allotted. However, for ease of use and access across the company, Amgen should install
the web-based version of Expert Choice called Comparion mt .
As discussed in Section 3.2, the sole use of net present value to analyze the financials of a
project may prevent beneficial innovations from being implemented. Therefore, Amgen should try
to re-implement a real options model that can take into account the great amount of uncertainty
in technology projects and can also sometimes better capture the potential long-term upsides of
a given technology. The financial analysis from a real options model can easily replace the net
present value analysis used in the case studies in this thesis.
Concurrent with the decision-making process described in this thesis, Amgen has also sought
to overhaul its technology advancement process. They have organized a Technology Advance-
ment team composed of senior managers that will meet quarterly to discuss upcoming technology
projects with the goal to prioritize, select, and facilitate the projects that should be advanced. The
AHP decision-making process is very apt for these choices and should be utilized by this body in
order to make their decisions.
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Appendix A. Drug Substance Container 3rd
Level Hierarchy Criteria
Table 6: Drug Substance Container - Finance Sub-criteria.
Capital Cost Operating Cost Cost of Quality
Drug Substance Container Cost Maintenance Cost Validation
Associated Equipment Cost Cleaning & Sterilization Cost Investigations
Facility Modification Cost Disposal Cost Raw Material Risks
Operations Labor Cost
Transportation Cost
Impact to Plant Capacity
Table 7: Drug Substance Container - Supply Sub-criteria.
Capacity Ability to Hold in Warehouse Delivery Risk
Meet Current Safety Stock <= 3 Years Ability to Supply Business Continuity Plan
Annual Demand Globally
Meet Future Safety Stock > 3 Years On-time, Correct, Transparency / Risk of
Demand Complete Total Supply Chain
Ship Under Stipulated Low Risk of Insolvency or
Conditions Market Exit
Table 8: Drug Substance Container - Quality Sub-criteria.
Supplier Quality Regulatory Quality-Related Container Requirements
Segmentation Results Support of Regional Container Version Available for Small-Scale
Requirements Experimental Work
Supplier has Supply/Quality Ease of Acceptance Leachable / Extractable Profile
Agreement with Sub-Supplier
Adherence to Incoming Functionality
Acceptance Criteria
Adherence to Quality and Supply Chain Security
Supply Agreement Templates
Stability
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Table 9: Drug Substance Container - Drug Product Process Sub-criteria.
Environmental Factors
Re-usable Containers
Resistant to Cleaning Agents
Biodegradable Container
Capabilities
Scale-down Model of Freeze / Thaw
Behavior
Range of Fill Volumes that can be Validated
Ability to Sample from Drug Substance
Container
Closed Processing
Ability to Aseptically Aliquot from Container
Easy to Dispense with High Yield
Ability to Mix in Container After Thawing
Accommodate Static or Dynamic Thawing
Easy to Thaw Dug Substance
Table 10: Drug Substance Container - Logistics Sub-criteria.
Storage
Protect Product from Light
Exposure
Maintenance of Container Closure
Amgen Business Continuity Plan
Labelling / Re-labelling
Capacity for Long-term
Storage/Weight of the Vessel
Empty or Full Tanks (Warehouse
or Return to Warehouse)
Ergonomically Friendly
Ease of Inventory Reconciliation
Transportation
Tamper Proofing
Ergonomically Friendly
Air Shipments Dry Ice
Requirements
Import / Export Documentation
Risks
Shipping Quanitities (Amount at
Risk)
Inspection from Customs Opening
the Container
Training of Handling the Vessels
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Freeze / Thaw Dynamics
Freeze Time
Thaw Time
Table 11: Drug Substance Container - Drug Substance Fill Process Sub-criteria.
Cleaning & Mechanical Contact Manpower Design - Peripheral Storage &
Sterilization Strength Surface for Fill Product-Related Equipment Warehous-
Compatability Operation ing
Ease of Able to Inert to Product Number of Shaped to Allow Quick Maintenance of Staging
Cleaning Withstand Excipients Staff and Uniform Freeze to Equipment Space
Handling Required to the Center
During Perform Fill
Cleaning
Ease of Able to Acceptable Ergonomic Controllable Space Storage
Sterilization Withstand Levels of Concerns Freeze/Thaw rate for Requirement Space
Sterilization / Leachables / Sensitive Proteins for Peripheral
Autoclaving Extractables Equipment
Low Particle Resistant to Low Protein Training Self-standing Storage Con-
Count Prior to Crack, Chip, Binding Complexity figuration
Cleaning Abrasion, and
Drop Fracture
Maintains Resistant to Low Gas Lifetime Protection
Sterility for Stress from Permeability from Light
Prolonged Freezing
Period
Resistant to Low PS-20 Allows Closed
Shock and Binding Processing
Stress from
Transport
No Particle Allows Aseptic
Shedding Handling
Surface Finish Allows Easy Transfer in
Case of Refiltration
Allows Sampling
Ease of Validating
Container Integrity
Allows Accurate
Measurement of Weight
Light Exposure Control
Anti-static Property
Ability to Perform
Visual Inspection
Compatability with
Existing Cleaning and
Sterilization Equipment
Container Size Meets
Drug Product Fill
Requirements
Process Cycle Time
Prep Time for
Containers
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